BYSIのチャート
BYSIの企業情報
| symbol | BYSI |
|---|---|
| 会社名 | BeyondSpring Inc （ビヨンドスプリング） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product Plinabulin into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe grade 4 neutropenia and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). Plinabulin has also entered in a Phase I/II clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab. The Company's BPI-002 program is based on an oral small molecule agent which induces T-cell activation. The Company's IkappaB kinase (IKK) program BPI-003 is based on a small molecule inhibitor of IKK a protein kinase. ビヨンドスプリングは米国のバイオ医薬品メ―カ―。末期の免疫性腫瘍の治療薬も含む、革新的ながん治療薬の開発に注力する。主要製品候補の「プリナブリン」は、進行性非小細胞肺がんの治療薬及び好中球減少症の予防薬として臨床段階中である。また、モノクロ―ナル抗体医薬品のニボルマブとプリナブリンを組み合わせた治療薬も開発中。本社はニューヨーク。 BeyondSpring is a global, clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies. BeyondSpring's lead asset, plinabulin, a first-in-class agent as an immune and stem cell modulator, is in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of non-small cell lung cancer (NSCLC) and Phase 3 clinical programs in the prevention of CIN. The U.S. FDA granted Breakthrough Therapy designation to plinabulin for concurrent administration with myelosuppressive chemotherapeutic regimens in patients with non-myeloid malignancies for the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring has strong R&D capabilities with a robust pipeline in addition to plinabulin, including three immuno-oncology assets and a drug discovery platform using the protein degradation pathway, which is being developed in a subsidiary company, Seed Therapeutics, Inc. The Company also has a seasoned management team with many years of experience bringing drugs to the global market. BeyondSpring is headquartered in New York City. |
| 本社所在地 | 28 Liberty Street 39th Floor New York NY 10005 USA |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | +1 646-528-4184 |
| 設立年月日 | 41944 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2017年 |
| 従業員数 | 38人 |
| url | www.beyondspringpharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/bysi |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -64.95400 |
| 終値（lastsale） | 23.5345 |
| 時価総額（marketcap） | 528013028.719 |
| 時価総額 | 時価総額（百万ドル） 529.95460 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 508.41660 |
| 当期純利益 | 当期純利益（百万ドル） -58.02300 |
| 決算概要 | 決算概要 BRIEF: For the three months ended 31 March 2018 Beyondspring Inc revenues was not reported. Net loss decreased 71% to $13.7M. Lower net loss reflects Research_Development decrease of 70% to $14.1M (expense) General and administrative decrease of 30% to $728K (expense) Foreign Exchange Gain Net increase from $74K to $332K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$3.01 to -$0.77. |
BYSIのテクニカル分析
BYSIのニュース
BeyondSpring Announces a Late-Breaking Poster Presentation of PROTECTIVE-2 Phase 3 Data Showing Plinabulin, in Combination with Pegfilgrastim, Reverses the Immune-Suppressive Effects of Pegfilgrastim and Offers Superior Prevention of Chemotherapy-Induced Neutropenia (CIN) at the FOCIS Annual Meeting 2021/06/08 11:00:00 Intrado Digital Media
Presentation data demonstrates that plinabulin, in combination with pegfilgrastim, not only improves CIN prevention but also reverses some of the immune suppressive profile of monotherapy pegfilgrastim Presentation data demonstrates that plinabulin, in combination with pegfilgrastim, not only improves CIN prevention but also reverses some of the immune suppressive profile of monotherapy pegfilgrastim
BeyondSpring Announces a Late-Breaking Poster Presentation of PROTECTIVE-2 Phase 3 Data Showing Plinabulin, in Combination with Pegfilgrastim, Reverses the Immune-Suppressive Effects of Pegfilgrastim and Offers Superior Prevention of Chemotherapy-Induced 2021/06/08 11:00:00 Wallstreet:Online
Presentation data demonstrates that plinabulin, in combination with pegfilgrastim, not only improves CIN prevention but also reverses some of the immune suppressive profile of monotherapy pegfilgrastim NEW YORK, June 08, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the Company or BeyondSpring) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative
BeyondSpring reports positive plinabulin combo data for prevention of chemotherapy-induced neutropenia 2021/06/07 13:44:22 Seeking Alpha
BeyondSpring Announces Three Presentations Highlighting Positive Clinical Outcome Data from the Phase 3 Program of Plinabulin in Combination with Pegfilgrastim for the Prevention of Chemotherapy-Induced Neutropenia at the American Society of Clinical Onco 2021/06/07 11:00:00 Wallstreet:Online
- Data demonstrate that combination of plinabulin and pegfilgrastim offers superior benefit for reducing the incidence and severity of febrile neutropenia (FN) and hospitalization, with better quality-of-life (QoL), compared to pegfilgrastim alone NEW YORK, June 07, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the Company or BeyondSpring) (NASDAQ: BYSI), a global biopharmaceutical
BeyondSpring Files US-China Application For Plinabulin G-CSF Treatment In Chemo-Induced Neutropenia 2021/04/01 11:11:28 Benzinga
BeyondSpring Inc (NASDAQ: BYSI ) has submitted marketing applications in the U.S. and China seeking approval for plinabulin in combination with granulocyte colony-stimulating factor (G-CSF) for the prevention of chemotherapy-induced neutropenia (CIN). Neutropenia is … Full story available on Benzinga.com
Neutropenia Treatment Market to see Huge Growth by 2026 | Mylan, BeyondSpring, Myelo Therapeutics 2021/01/27 17:10:26 OpenPR
Stay up-to-date and exploit latest trends of Neutropenia Treatment Market with latest edition released by AMA. Neutropenia Treatment Market Comprehensive Study is an expert and top to bottom investigation on the momentum condition of the worldwide Neutropenia Treatment industry with an
5 Top Stock Gainers for Wednesday: Bilibili, Dermtech 2020/12/30 21:22:46 The Street
Bilibili, Bionano Genomics, DermTech, Baidu and BeyondSpring are five top stock gainers for Wednesday.
Mid-Afternoon Market Update: Dow Falls Over 100 Points; BeyondSpring Shares Plunge - Stocks News Feed 2020/11/18 19:31:24 Stocks News Feed
Toward the end of trading Wednesday, the Dow traded down 0.45% to 29,650.53 while the NASDAQ fell 0.24% to 11,870.69. The S&P also fell, dropping 0.49% to 3,591.72. The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 11,360,120 cases with around 248,700 deaths. India confirmed a… Read More »Mid-Afternoon Market Update: Dow Falls Over 100 Points; BeyondSpring Shares Plunge
BeyondSpring (NASDAQ:BYSI) Stock Price Up 5% 2020/10/25 04:12:46 The Lincolnian
BeyondSpring Inc. (NASDAQ:BYSI)’s share price rose 5% during trading on Friday . The stock traded as high as $15.50 and last traded at $14.83. Approximately 191,225 shares were traded during trading, an increase of 97% from the average daily volume of 97,298 shares. The stock had previously closed at $14.12. BYSI has been the topic […]
Neutropenia Treatment Market to see Huge Growth by 2026 | Mylan, BeyondSpring, Myelo Therapeutics 2021/01/27 17:10:26 OpenPR
Stay up-to-date and exploit latest trends of Neutropenia Treatment Market with latest edition released by AMA. Neutropenia Treatment Market Comprehensive Study is an expert and top to bottom investigation on the momentum condition of the worldwide Neutropenia Treatment industry with an
5 Top Stock Gainers for Wednesday: Bilibili, Dermtech 2020/12/30 21:22:46 The Street
Bilibili, Bionano Genomics, DermTech, Baidu and BeyondSpring are five top stock gainers for Wednesday.
Mid-Afternoon Market Update: Dow Falls Over 100 Points; BeyondSpring Shares Plunge - Stocks News Feed 2020/11/18 19:31:24 Stocks News Feed
Toward the end of trading Wednesday, the Dow traded down 0.45% to 29,650.53 while the NASDAQ fell 0.24% to 11,870.69. The S&P also fell, dropping 0.49% to 3,591.72. The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 11,360,120 cases with around 248,700 deaths. India confirmed a… Read More »Mid-Afternoon Market Update: Dow Falls Over 100 Points; BeyondSpring Shares Plunge
BeyondSpring (NASDAQ:BYSI) Stock Price Up 5% 2020/10/25 04:12:46 The Lincolnian
BeyondSpring Inc. (NASDAQ:BYSI)’s share price rose 5% during trading on Friday . The stock traded as high as $15.50 and last traded at $14.83. Approximately 191,225 shares were traded during trading, an increase of 97% from the average daily volume of 97,298 shares. The stock had previously closed at $14.12. BYSI has been the topic […]